413 related articles for article (PubMed ID: 29571273)
61. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
62. Fall-related healthcare use and costs in neurogenic orthostatic hypotension with Parkinson's disease.
François C; Biaggioni I; Shibao C; Ogbonnaya A; Shih HC; Farrelly E; Ziemann A; Duhig A
J Med Econ; 2017 May; 20(5):525-532. PubMed ID: 28125950
[TBL] [Abstract][Full Text] [Related]
63. Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods.
Aly A; Onukwugha E; Woods C; Mullins CD; Kwok Y; Qian Y; Arellano J; Balakumaran A; Hussain A
BMC Med Res Methodol; 2015 Aug; 15():65. PubMed ID: 26286392
[TBL] [Abstract][Full Text] [Related]
64. Hospital visits among women with skeletal-related events secondary to breast cancer and bone metastases: a nationwide population-based cohort study in Denmark.
Svendsen ML; Gammelager H; Sværke C; Yong M; Chia VM; Christiansen CF; Fryzek JP
Clin Epidemiol; 2013; 5():97-103. PubMed ID: 23576882
[TBL] [Abstract][Full Text] [Related]
65. Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer.
Yong C; Onukwugha E; Mullins CD
Curr Opin Oncol; 2014 May; 26(3):274-83. PubMed ID: 24626126
[TBL] [Abstract][Full Text] [Related]
66. Healthcare resource utilization among commercially insured patients with cold agglutinin disease in the United States.
Su J; Bylsma LC; Jiang X; Morales Arias J; Jain N; Nordyke RJ
J Med Econ; 2020 Aug; 23(8):902-907. PubMed ID: 32362156
[No Abstract] [Full Text] [Related]
67. Burden of Crohn's disease in the United States: long-term healthcare and work-loss related costs.
Manceur AM; Ding Z; Muser E; Obando C; Voelker J; Pilon D; Kinkead F; Lafeuille MH; Lefebvre P
J Med Econ; 2020 Oct; 23(10):1092-1101. PubMed ID: 32609019
[TBL] [Abstract][Full Text] [Related]
68. Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population.
Wu B; Li SS; Song J; Pericone CD; Behl AS; Dawson NA
J Med Econ; 2020 Jan; 23(1):54-63. PubMed ID: 31589086
[No Abstract] [Full Text] [Related]
69. Costs and health resource use in patients with X-linked myotubular myopathy: insights from US commercial claims.
Sacks NC; Healey BE; Cyr PL; Slocomb T; James E; Beggs AH; Graham RJ
J Manag Care Spec Pharm; 2021 Aug; 27(8):1019-1026. PubMed ID: 33843254
[No Abstract] [Full Text] [Related]
70. Healthcare Costs Among Patients with Heart Failure: A Comparison of Costs between Matched Decedent and Survivor Cohorts.
Obi EN; Swindle JP; Turner SJ; Russo PA; Altan A
Adv Ther; 2017 Jan; 34(1):261-276. PubMed ID: 27933568
[TBL] [Abstract][Full Text] [Related]
71. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
Henk HJ; Kaura S
J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235
[TBL] [Abstract][Full Text] [Related]
72. Societal burden of cluster headache in the United States: a descriptive economic analysis.
Ford JH; Nero D; Kim G; Chu BC; Fowler R; Ahl J; Martinez JM
J Med Econ; 2018 Jan; 21(1):107-111. PubMed ID: 29125368
[TBL] [Abstract][Full Text] [Related]
73. Healthcare resource utilization and direct medical costs associated with index and recurrent
Feuerstadt P; Stong L; Dahdal DN; Sacks N; Lang K; Nelson WW
J Med Econ; 2020 Jun; 23(6):603-609. PubMed ID: 31999199
[No Abstract] [Full Text] [Related]
74. Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.
Schultz NM; Penson DF; Wilson SD; Song Y; Yang H; Ramaswamy K; Lowentritt B
J Manag Care Spec Pharm; 2019 Aug; 25(8):889-897. PubMed ID: 31172866
[TBL] [Abstract][Full Text] [Related]
75. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis.
Eby EL; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA
J Med Econ; 2013; 16(4):529-38. PubMed ID: 23363330
[TBL] [Abstract][Full Text] [Related]
76. Healthcare resource utilization among patients diagnosed with idiopathic pulmonary fibrosis in the United States.
Wu N; Yu YF; Chuang CC; Wang R; Benjamin NN; Coultas DB
J Med Econ; 2015 Apr; 18(4):249-57. PubMed ID: 25428658
[TBL] [Abstract][Full Text] [Related]
77. Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.
Pilon D; Alcusky M; Xiao Y; Thompson-Leduc P; Lafeuille MH; Lefebvre P; Benson C
J Med Econ; 2018 Feb; 21(2):135-143. PubMed ID: 28895766
[TBL] [Abstract][Full Text] [Related]
78. Characterizing downstream healthcare resource utilization and costs based on prior utilization patterns of immediate-release hydrocodone.
Ben-Joseph R; Bell JA; Chitnis A; Kansal A; Holly P; Paramore C; Wild H
J Med Econ; 2016; 19(2):169-80. PubMed ID: 26451633
[TBL] [Abstract][Full Text] [Related]
79. Evaluation of healthcare resource utilization and incremental economic burden of patients with chronic myeloid leukemia after disease progression to blast phase.
Jabbour EJ; Lin J; Siegartel LR; Lingohr-Smith M; Menges B; Makenbaeva D
J Med Econ; 2017 Sep; 20(9):1007-1012. PubMed ID: 28681664
[TBL] [Abstract][Full Text] [Related]
80. Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population.
Rice JB; White AG; Johnson M; Wagh A; Qin Y; Bartels-Peculis L; Ciepielewska G; Nelson WW
J Med Econ; 2018 Sep; 21(9):846-852. PubMed ID: 29741439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]